{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:18:22Z","timestamp":1773875902489,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40261-026-01530-6","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:52:30Z","timestamp":1773237150000},"page":"359-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5615-0253","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-9527","authenticated-orcid":false,"given":"Alesha","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2625-2121","authenticated-orcid":false,"given":"Carlo A.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"Suppl_1","key":"1530_CR1","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes: 2024. Diabetes Care. 2024;47(Suppl_1):S158\u201378. https:\/\/doi.org\/10.2337\/dc24-S009.","journal-title":"Diabetes Care"},{"issue":"12","key":"1530_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2.","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","journal-title":"Diabetologia"},{"key":"1530_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2018","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;43:487\u201393. https:\/\/doi.org\/10.2337\/dci19-0066.","journal-title":"Diabetes Care"},{"issue":"22","key":"1530_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"21","key":"1530_CR5","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386(21):2024\u201334. https:\/\/doi.org\/10.1056\/NEJMra2115011.","journal-title":"N Engl J Med"},{"issue":"4","key":"1530_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"6","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"23","key":"1530_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"1530_CR9","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"issue":"1","key":"1530_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001258","volume":"4","author":"C Moucheraud","year":"2019","unstructured":"Moucheraud C, Lenz C, Latkovic M, Wirtz VJ. The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ Glob Health. 2019;4(1):e001258. https:\/\/doi.org\/10.1136\/bmjgh-2018-001258.","journal-title":"BMJ Glob Health"},{"issue":"9","key":"1530_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14060","volume":"75","author":"ER Weeda","year":"2021","unstructured":"Weeda ER, Muraoka AK, Brock MD, Cannon JM. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis. Int J Clin Pract. 2021;75(9):e14060. https:\/\/doi.org\/10.1111\/ijcp.14060.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"1530_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1530_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"key":"1530_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"6","key":"1530_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2146\/ajhp070248","volume":"65","author":"DQ Pham","year":"2008","unstructured":"Pham DQ, Nogid A, Plakogiannis R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. Am J Health-Syst Pharm. 2008;65(6):521\u201331. https:\/\/doi.org\/10.2146\/ajhp070248.","journal-title":"Am J Health-Syst Pharm"},{"key":"1530_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"1530_CR17","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group, & Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2011;343:5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ (Clin Res Ed)."},{"key":"1530_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ (Clin Res Ed)."},{"key":"1530_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"2","key":"1530_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13696998.2016.1238386","volume":"20","author":"U Permsuwan","year":"2017","unstructured":"Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017;20(2):171\u201381. https:\/\/doi.org\/10.1080\/13696998.2016.1238386.","journal-title":"J Med Econ"},{"key":"1530_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CEOR.S113559","volume":"8","author":"U Permsuwan","year":"2016","unstructured":"Permsuwan U, Dilokthornsakul P, Saokaew S, Thavorn K, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. Clinicoecon Outcomes Res. 2016;8:521\u20139. https:\/\/doi.org\/10.2147\/CEOR.S113559.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"1530_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s13300-021-01088-w","volume":"12","author":"C Deerochanawong","year":"2021","unstructured":"Deerochanawong C, Vareesangthip K, Piyayotai D, Thongsuk D, Pojchaijongdee N, Permsuwan U. Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand. Diabetes Ther. 2021;12(7):1947\u201363. https:\/\/doi.org\/10.1007\/s13300-021-01088-w.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1530_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s13300-023-01371-y","volume":"14","author":"C Deerochanawong","year":"2023","unstructured":"Deerochanawong C, Krittayaphong R, Romano JGU, Rhee NA, Permsuwan U. Cost-utility of liraglutide plus standard of care versus standard of care in people with type 2 diabetes and cardiovascular risk in Thailand. Diabetes Ther. 2023;14(3):531\u201352. https:\/\/doi.org\/10.1007\/s13300-023-01371-y.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1530_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81747-7","volume":"15","author":"N Chitpim","year":"2025","unstructured":"Chitpim N, Leelahavarong P, Prawjaeng J, Ittiphisit S, Srinonprasert V, Kongmalai T. A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand. Sci Rep. 2025;15(1):249. https:\/\/doi.org\/10.1038\/s41598-024-81747-7.","journal-title":"Sci Rep"},{"issue":"10","key":"1530_CR25","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.7326\/M21-2941","volume":"175","author":"JG Choi","year":"2022","unstructured":"Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175(10):1392\u2013400. https:\/\/doi.org\/10.7326\/M21-2941.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1530_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis: principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"issue":"10","key":"1530_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002397","volume":"14","author":"A Bilinski","year":"2017","unstructured":"Bilinski A, Neumann P, Cohen J, Thorat T, McDaniel K, Salomon JA. When cost-effective interventions are unaffordable: integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Med. 2017;14(10):e1002397. https:\/\/doi.org\/10.1371\/journal.pmed.1002397.","journal-title":"PLoS Med"},{"issue":"1","key":"1530_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02053-6","volume":"22","author":"SW Quist","year":"2023","unstructured":"Quist SW, van Schoonhoven AV, Bakker SJL, et al. Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc Diabetol. 2023;22(1):328. https:\/\/doi.org\/10.1186\/s12933-023-02053-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1530_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/dom.14979","volume":"25","author":"WJ Valentine","year":"2023","unstructured":"Valentine WJ, Hoog M, Mody R, Belger M, Pollock R. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0\u2009mg for the management of type 2 diabetes in the United States. Diabetes Obes Metab. 2023;25(5):1292\u2013300. https:\/\/doi.org\/10.1111\/dom.14979.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1530_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.18553\/jmcp.2024.30.2.153","volume":"30","author":"R Mody","year":"2024","unstructured":"Mody R, Valentine WJ, Hoog M, Sharland H, Belger M. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: a long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States. J Manag Care Spec Pharm. 2024;30(2):153\u201362. https:\/\/doi.org\/10.18553\/jmcp.2024.30.2.153.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1530_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13300-024-01675-7","volume":"16","author":"T Aranishi","year":"2025","unstructured":"Aranishi T, Igarashi A, Hara K, et al. The long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg for the treatment of people with type 2 diabetes in Japan. Diabetes Ther. 2025;16(3):431\u201345. https:\/\/doi.org\/10.1007\/s13300-024-01675-7.","journal-title":"Diabetes Ther."},{"issue":"2","key":"1530_CR32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s12325-024-03084-5","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Ohara K, Matsuda H, Morii J, Jagannathan S, Filomeno R. Cost-effectiveness analysis of finerenone for treatment of chronic kidney disease in patients with type 2 diabetes from Japanese payer perspective. Adv Ther. 2025;42(2):995\u20131008. https:\/\/doi.org\/10.1007\/s12325-024-03084-5.","journal-title":"Adv Ther"},{"issue":"1","key":"1530_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/dom.15997","volume":"27","author":"C Zheng","year":"2025","unstructured":"Zheng C, Wu J, Li N, et al. Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States. Diabetes Obes Metab. 2025;27(1):165\u201373. https:\/\/doi.org\/10.1111\/dom.15997.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1530_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2025.2451526","volume":"28","author":"D Cherney","year":"2025","unstructured":"Cherney D, Drzewiecka A, Folkerts K, et al. Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model. J Med Econ. 2025;28(1):196\u2013206. https:\/\/doi.org\/10.1080\/13696998.2025.2451526.","journal-title":"J Med Econ"},{"issue":"3","key":"1530_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"issue":"1","key":"1530_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1530_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41440-023-01569-4","volume":"47","author":"S Toyoda","year":"2024","unstructured":"Toyoda S. Blood pressure lowering effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). Hypertens Res. 2024;47(3):803\u20134. https:\/\/doi.org\/10.1038\/s41440-023-01569-4.","journal-title":"Hypertens Res"},{"issue":"8","key":"1530_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805","volume":"103","author":"HK Kim","year":"2024","unstructured":"Kim HK, Biessels GJ, Yu MH, et al. SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology. 2024;103(8):e209805. https:\/\/doi.org\/10.1212\/WNL.0000000000209805.","journal-title":"Neurology"},{"key":"1530_CR39","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"ACCORD Study Group","year":"2008","unstructured":"ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"1530_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassa\u00ef B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.","journal-title":"BMJ"},{"key":"1530_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110625","volume":"198","author":"CT Yang","year":"2023","unstructured":"Yang CT, Yao WY, Ou HT, Kuo S. Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: a model-based cost-effectiveness analysis using real-world data. Diabetes Res Clin Pract. 2023;198:110625. https:\/\/doi.org\/10.1016\/j.diabres.2023.110625.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1530_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40273-023-01286-3","volume":"41","author":"X Li","year":"2023","unstructured":"Li X, Hoogenveen R, El Alili M, et al. Cost-effectiveness of SGLT2 inhibitors in a real-world population: a MICADO model-based analysis using routine data from a GP registry. Pharmacoeconomics. 2023;41(10):1249\u201362. https:\/\/doi.org\/10.1007\/s40273-023-01286-3.","journal-title":"Pharmacoeconomics"},{"key":"1530_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109152","volume":"183","author":"F Becker","year":"2022","unstructured":"Becker F, Dakin HA, Reed SD, et al. Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial. Diabetes Res Clin Pract. 2022;183:109152. https:\/\/doi.org\/10.1016\/j.diabres.2021.109152.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1530_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"11","key":"1530_CR45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","volume":"37","author":"S Kent","year":"2019","unstructured":"Kent S, Becker F, Feenstra T, et al. The challenge of transparency and validation in health economic decision modelling. Pharmacoeconomics. 2019;37(11):1305\u201312.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1530_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","volume":"36","author":"M Asaria","year":"2016","unstructured":"Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36(1):8\u201319. https:\/\/doi.org\/10.1177\/0272989X15583266.","journal-title":"Med Decis Making"},{"issue":"2","key":"1530_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1017\/S1744133109004903","volume":"4","author":"R Cookson","year":"2009","unstructured":"Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Econ Policy Law. 2009;4(2):231\u201345. https:\/\/doi.org\/10.1017\/S1744133109004903.","journal-title":"Health Econ Policy Law"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01530-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:35:31Z","timestamp":1773848131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01530-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01530-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dan Li, Alesha Smith and Carlo A. Marra have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary materials. No additional datasets were created.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DL and AS developed and executed the search strategy and conducted the literature searches independently. CM cross-checked the search results for completeness and accuracy. DL, CM and AS independently screened titles and abstracts and reviewed full-text articles for eligibility, with all decisions resolved by consensus. DL and AS independently extracted the data using a predefined extraction form, and CM verified data completeness and internal consistency. DL drafted the manuscript. All authors reviewed, revised and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}